Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3′-azido-2′,3′- dideoxypurine nucleosides

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3715-3719

  Sluis Cremer, Nicolas ^a   Koontz, Dianna ^a   Bassit, Leda ^b   Hernandez Santiago, Brenda I ^b   Detorio, Mervi ^b   Rapp, Kim L ^b   Amblard, Franck ^b   Bondada, Lavanya ^b   Grier, Jason ^b   Coats, Steven J ^c   Schinazi, Raymond F ^b   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RFS Pharma LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' AZIDO 2',3' DIDEOXYADENOSINE; 3' AZIDO 2',3' DIDEOXYGUANOSINE; ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; MITOCHONDRIAL DNA; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA CONTENT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; HELA CELL; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL TOXICITY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS MUTATION; VIRUS RECOMBINANT;

ANTI-HIV AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70349096395     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00392-09     Document Type: Article

References (25)

1. Almond, M. R., J. L. Collins, B. E. Reitter, J. L. Rideout, G. A. Freeman, and M. H. St. Clair. 1991. Synthesis of 2-amino-9-(3′-azido- 2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and Azdd- Guo. Tetrahedron Lett. 32:5745-5748.
2. Baba, M., R. Pauwels, J. Balzarini, P. Herdewijn, and E. De Clercq. 1987. Selective inhibition of human immunodeficiency virus (HIV) by 3′-azido-2′, 3′-dideoxyguanosine in vitro. Biochem. Biophys. Res. Commun. 145:1080-1086.
3. Brehm, J. H., D. Koontz, J. D. Meteer, V. Pathak, N. Sluis-Cremer, and J. W. Mellors. 2007. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J. Virol. 81:7852-7859. (Pubitemid 47101471)
4. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
5. Cihlar, T., A. S. Ray, C. G. Boojamra, L. Zhang, H. Hui, G. Laflamme, J. E. Vela, D. Grant, J. Chen, F. Myrick, K. L. White, Y. Gao, K. Y. Lin, J. L. Douglas, N. T. Parkin, A. Carey, R. Pakdaman, and R. L. Mackman. 2008. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob. Agents Chemother. 52:655-665.
6. Freeman, G. A., S. R. Shaver, J. L. Rideout, and S. A. Short. 1995. 2-Amino-9-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranosyl) -6-substituted-9H-purines: synthesis and anti-HIV activity. Bioorg. Med. Chem. 3:447-458.
7. Gao, W. Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Investig. 91:2326-2333.
8. Goody, R. S., B. Muller, and T. Restle. 1991. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett. 291:1-5.
9. Hartmann, H., G. Hunsmann, and F. Eckstein. 1987. Inhibition of HIV-induced cytopathogenicity in vitro by 3′-azido-2′,3′- dideoxyguanosine. Lancet i:40-41.
10. Herdewijn, P., J. Balzarini, M. Baba, R. Pauwels, A. Van Aerschot, G. Janssen, and E. De Clercq. 1988. Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides. J. Med. Chem. 31:2040-2048.
11. Imazawa, M., and F. Eckstein. 1978. Synthesis of 3′-azido-2′, 3′-dideoxyribofuranosylpurines. J. Org. Chem. 43:3044-3048.
12. Johnson, K. A. 1995. Rapid quench kinetic analysis of polymerases, adenosine triphosphatases, and enzyme intermediates. Methods Enzymol. 249:38-61.
13. Johnson, M. R., K. Wang, J. B. Smith, M. J. Heslin, and R. B. Diasio. 2000. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 278:175-184.
14. Le Grice, S. F., C. E. Cameron, and S. J. Benkovic. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
15. Le Grice, S. F., and F. Gruninger-Leitch. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187:307-314.
16. Meteer, J., D. Koontz, K. L. Rapp, M. Detorio, M. Ruckstuhl, R. F. Schinazi, and J. W. Mellors. 2008. Novel resistance profile of the potent nucleoside analogue reverse transcriptase inhibitor 3′-azido-2′, 3′-dideoxyguanosine. Antivir. Ther. 13:A5.
17. Parikh, U. M., D. L. Koontz, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49:1139-1144.
18. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
19. Schinazi, R. F., D. L. Cannon, B. H. Arnold, and D. Martino-Saltzman. 1988. Combinations of isoprinosine and 3′-azido-3′-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 32:1784-1787.
20. Schinazi, R. F., B. I. Hernandez-Santiago, and S. J. Hurwitz. 2006. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antivir. Res. 71:322-334.
21. Schinazi, R. F., J. P. Sommadossi, V. Saalmann, D. L. Cannon, M. Y. Xie, G. C. Hart, G. A. Smith, and E. F. Hahn. 1990. Activities of 3′-azido-3′- deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 34:1061-1067.
22. Sharma, P. L., V. Nurpeisov, B. Hernandez-Santiago, T. Beltran, and R. F. Schinazi. 2004. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr. Top. Med. Chem. 4:895-919.
23. Sluis-Cremer, N., D. Arion, U. Parikh, D. Koontz, R. F. Schinazi, J. W. Mellors, and M. A. Parniak. 2005. The 3′-azido group is not the primary determinant of 3′-azido-3′-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J. Biol. Chem. 280:29047-29052.
24. Stein, D. S., and K. H. Moore. 2001. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 21:11-34.
25. Stuyver, L. J., S. Lostia, M. Adams, J. S. Mathew, B. S. Pai, J. Grier, P. M. Tharnish, Y. Choi, Y. Chong, H. Choo, C. K. Chu, M. J. Otto, and R. F. Schinazi. 2002. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46:3854-3860.